Yiheng Capital Management Portfolio holdings
Top Buys
| 1 |
JD.com
JD
|
+$62M |
| 2 |
indie Semiconductor
INDI
|
+$12.4M |
| 3 |
Sabre
SABR
|
+$5.07M |
| 4 |
Denali Therapeutics
DNLI
|
+$3.82M |
| 5 |
AKRO
Akero Therapeutics
AKRO
|
+$3.47M |
Top Sells
| 1 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$52.2M |
| 2 |
TransDigm Group
TDG
|
+$28.5M |
| 3 |
PENG
Penguin Solutions Inc
PENG
|
+$17.4M |
| 4 |
HIMX
Himax Technologies
HIMX
|
+$9.64M |
Sector Composition
| 1 | Consumer Discretionary | 12.89% |
| 2 | Communication Services | 11.62% |
| 3 | Healthcare | 9.51% |
| 4 | Consumer Staples | 8.26% |
| 5 | Technology | 7.92% |
Similar funds
Yiheng Capital Management's Q2 2023 Portfolio in Review
As of Q2 2023, Yiheng Capital Management held 35 positions worth $1.85B, down 27% from $2.53B the previous quarter. Its ten largest holdings account for 82% of the portfolio.
Yiheng Capital Management withdrew a net $273M in Q2 2023, closing 4 positions and reducing 5 holdings. Its most notable exit was IVERIC bio, Inc. Common Stock, an estimated $52.2M position sold in full.
By sector, the portfolio is most concentrated in Consumer Discretionary at 13% of assets, up from 9% a quarter earlier, followed by Communication Services and Healthcare.
Against the trend, Yiheng Capital Management added an estimated $62M to JD.com.
- Yiheng Capital Management added most to JD.com in Q2 2023, an estimated $62M increase.
- Yiheng Capital Management's biggest Q2 2023 reduction was TransDigm Group, cutting an estimated $28.5M.
- Yiheng Capital Management fully exited IVERIC bio, Inc. Common Stock in Q2 2023, selling an estimated $52.2M.
- Yiheng Capital Management's ten largest holdings make up 82% of its $1.85B portfolio in Q2 2023.
- Yiheng Capital Management opened 0 new positions and closed 4 in Q2 2023.
- Yiheng Capital Management's portfolio value fell 27% quarter-over-quarter to $1.85B.
Based on Yiheng Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.